Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14537318 | 0.74 | PIN1 (0.50) | HDAC9SIGMAR1HCAR2KDM1AMAOB | |
| SCHEMBL11294130 | 0.74 | HDAC9 (0.44) | HDAC9SIGMAR1HCAR2KDM1AMAOB | |
| SCHEMBL15026087 | 0.74 | PIN1 (0.50) | HDAC9SIGMAR1HCAR2KDM1AMAOB | |
| SCHEMBL7448215 | 0.72 | KDM4E (0.44) | HDAC9SIGMAR1HCAR2KDM1AMAOB | |
| SCHEMBL2468652 | 0.72 | KDM4E (0.44) | HDAC9SIGMAR1HCAR2KDM1AMAOB | |
| SCHEMBL8749372 | 0.72 | HDAC9 (0.43) | HDAC9HCAR2TDP1TACR1TACR3 | |
| SCHEMBL19361709 | 0.72 | HDAC9 (0.40) | HDAC9SIGMAR1HCAR2KDM1A | |
| SCHEMBL6975129 | 0.72 | KDM1A (0.42) | HDAC9SIGMAR1KDM1AMAOB | |
| SCHEMBL8054529 | 0.72 | KDM1A (0.42) | HDAC9SIGMAR1KDM1AMAOB | |
| SCHEMBL13389061 | 0.71 | KDM1A (0.42) | HDAC9SIGMAR1HCAR2KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3225627-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Northwest University (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | HDAC9 1931/4885SIGMAR1 4765/4885HCAR2 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.